Abbott took "a deliberately very different development path ... for the waveform" behind its Volt PFA system, said Dr.

With a key regulatory approval secured in Europe, Abbott Laboratories is joining the race to commercialize technology that ...

Abbott ABT recently announced CE Mark approval for the Volt Pulsed Field Ablation (“PFA”) system to treat patients battling atrial fibrillation (AFib). The development came earlier than expected, ...

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

Abbott Park, Illinois Saturday, March 29, 2025, 13:00 Hrs [IST] ...

With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...

On Thursday, analysts from Oppenheimer gave the company an “outperform” rating and a price target of $134, a 2-percent upside ...

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Though late to the party compared to other industry mammoths, Abbott joins a pulsed field ablation market poised for ...